Comparing intramuscular and intranasal Ketamin in procedural sedation of pediatrics between 2 and 15 years

Comparing intramuscular and intranasal Ketamin in pain reduction of pediatrics between 2 and 15 years during procedural sedation in emergency department

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014052417825N1

Enrollment

Registered

2014-07-06

Start date

2013-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

??Extremity Trauma. Musculoskeletal System and Connective Tissue Diseases

Interventions

Intervention 1: Intervention Group: Nasal spray of 1-2 mg/kg of Ketamin. Intervention 2: Control Group: Intramuscular injection of 1-2 mg/kg Ketamin.

Treatment - Drugs

Intervention Group: Nasal spray of 1-2 mg/kg of Ketamin

Control Group: Intramuscular injection of 1-2 mg/kg Ketamin

Eligibility

Sex/Gender

All

Age

2 Years to 15 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Necessity to perform different types of procedures including repair of lacerations in different sizes and in every region of body and also types of reductions in emergency department; Level of consciousness more than 15 in GCS format; Age between 2 and 15; Not suffering of any mental disorders; Consent of the patient for the procedures. Exclusion Criteria: Any past history of surgery on trachea or tracheal stenosis; Active lung infection; Intake of large amount of food during three hours before procedure; Cardiovascular diseases including angina and heart failure and hypertension; Trauma or head injury resulting in lowering level of consciousness or vomiting; Mass in CNS or hydrocephalus; Not well controlled seizure ; Glaucoma or Acute globe injury; Psychosis and Porphiria and Thyroid Disease and treatment with drugs of thyroid disease; Cardiac complications due to Ketamin administration; Not having consent of parents and guardians or the patient himself.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain Severity. Timepoint: Before, during and after drug administration. Method of measurement: Administration of Visual Analogue Scale and asking the patient to determine the picture representative of pain severity.	—

Secondary

Measure	Time frame
Changes in Vital Signs and Side effects. Timepoint: Before, during and after drug administration. Method of measurement: According to history and physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaeed Abbasi, Medical Doctor

Iran University of Medical Sciences

saieedabbasi@yahoo.com+98 21 6535 2022

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026